Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9691074 | 0.90 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1 | |
| SCHEMBL9691066 | 0.90 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1 | |
| SCHEMBL8500089 | 0.87 | CYSLTR2 (0.49) | PTGER1PTGER4PTGER3PTGER2CYSLTR2 | |
| SCHEMBL8500086 | 0.87 | CYSLTR2 (0.49) | PTGER1PTGER4PTGER3PTGER2CYSLTR2 | |
| SCHEMBL9691037 | 0.86 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL9691042 | 0.86 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL13950635 | 0.86 | CYSLTR2 (0.50) | PTGER1PTGER4PTGER3PTGER2CYSLTR2 | |
| SCHEMBL692870 | 0.83 | CYSLTR2 (0.52) | PTGER1PTGER4PTGER3PTGER2CYSLTR2 | |
| SCHEMBL692871 | 0.83 | CYSLTR2 (0.52) | PTGER1PTGER4PTGER3PTGER2CYSLTR2 | |
| SCHEMBL8496429 | 0.82 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474535-B1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO LTD (CN) | 2014-07-02 | — | — | EP | claimed |
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | claimed |
| EP-2474535-A1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2012-07-11 | — | — | EP | claimed |
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO. LTD. (CN) | 2012-06-28 | — | — | US | claimed |
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | disclosed |
| EP-2474535-A1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO. LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| WO-2011026398-A1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | 山东新时代药业有限公司 (CN) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | LTC4S, CMA1, PTGIS | PTGER1 481/4885PTGER4 308/4885PTGER3 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.